Table 2. Relationship between NY-ESO-1 antibody positivity and clinicopathological features in gastric cancer patients.
|
Variable |
NY-ESO-1 Ab |
P-value* |
|
|---|---|---|---|
| Negative | Positive | ||
|
Gender | |||
| Male | 223 (86.4) | 35 (13.6) | 0.04307 |
| Female |
99 (94.3) |
6 (5.7) |
|
|
Age (years) | |||
| >65 | 178 (88.6) | 23 (11.4) | 0.9209 |
| <65 |
144 (88.9) |
18 (11.1) |
|
|
Histological type | |||
| Differentiated | 143 (89.4) | 17 (10.6) | 0.5605 |
| Undifferentiated |
132 (87.4) |
19 (12.6) |
|
|
Depth of tumour invasion | |||
| cT1–T2 | 193 (92.8) | 15 (7.2) | 0.0044 |
| cT3–T4 |
129 (83.2) |
26 (16.8) |
|
|
Lymph node metastasis | |||
| Negative | 196 (97.0) | 6 (3.0) | <0.001 |
| Positive |
126 (78.3) |
35 (21.7) |
|
|
Distant metastasis | |||
| Negative | 277 (91.1) | 27 (8.9) | <0.001 |
| Positive |
45 (76.3) |
14 (23.7) |
|
|
Stage | |||
| I–II | 213 (96.4) | 8 (3.6) | <0.001 |
| III–IV | 109 (76.8) | 33 (23.2) | |
Abbreviations: Ab=antibody.
Fisher's exact test was used for the statistical analysis.
Values within parentheses are percentages.